METABOLIC EFFECTS OF 2-BROMO ERGOCRYPTINE-METHANE-SULPHONATE (CB 154) IN THE RAT

in Journal of Endocrinology
Authors:
K. K. MAHAJAN
Search for other papers by K. K. MAHAJAN in
Current site
Google Scholar
PubMed
Close
,
D. F. HORROBIN
Search for other papers by D. F. HORROBIN in
Current site
Google Scholar
PubMed
Close
, and
C. J. ROBINSON
Search for other papers by C. J. ROBINSON in
Current site
Google Scholar
PubMed
Close
Restricted access
Rent on DeepDyve

Sign up for journal news

Departments of Surgery and *Physiology, The Medical School, The University, Newcastle upon Tyne, NE1 7RU

(Received 12 September 1974)

CB 154 lowers plasma prolactin levels in animals (Flückiger, 1972) and in man (Lutterbeck, Pryor, Vangor & Wenner, 1971), in which it has been successfully used to treat galactorrhoea (Besser, Parke, Edwards, Forsyth, & McNeilly, 1972) and to suppress puerperal lactation (Varga, Lutterbeck, Pryor, Wenner, & Erb, 1972). Hyperprolactinaemia occurs in a number of clinical disorders (Horrobin, 1974) and CB 154 may also be used in these conditions. However, the metabolic effects of this potentially useful drug have not been fully investigated in man or in animals.

Twenty male Wistar rats weighing 140–160 g were used. Ten were given 1 mg CB 154 (Sandoz batch No. 193 H3) intraperitoneally at 12.00 h the day preceding the experiment, and a second injection of 1 mg was given at 08.30 h on the

 

  • Collapse
  • Expand